Copyright
©The Author(s) 2021.
World J Clin Oncol. Nov 24, 2021; 12(11): 1064-1071
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1064
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.1064
CHT + mEHT, n (%) | CHT, n (%) | P value | |
Median age (range) | 64 (38-82) | 69 (34-92) | 0.013 |
M | 39 (67) | 57 (57) | 0.204 |
F | 19 (33) | 43 (43) | |
Non-Metastatic | 16 (28) | 37 (37) | 0.223 |
Metastatic | 42 (72) | 63 (63) | |
Site of Metastases | |||
Liver | 40 (61) | 51 (70) | 0.164 |
Peritoneum | 16 (24) | 6 (8) | |
Lymph nodes | 9 (14) | 6 (8) | |
Lung | 1 (2) | 8 (11) | |
Previous surgery | 14 (24) | 24 (24) | 0.981 |
Previous RT | 1 (2) | 12 (12) | 0.023 |
Previous CHT | 52 (90) | 52 (52) | < 0.001 |
Number of previous CHT lines | |||
1 | 31 (60) | 25 (48) | 0.334 |
2 | 10 (19) | 18 (35) | 0.037 |
> 3 | 11 (21) | 9 (17) | 0.619 |
Type of CHT | |||
Gemox | 28 (54) | 12 (23) | 0.004 |
Gemcitabine | 12 (23) | 7 (13) | 0.205 |
Gemcitabine abraxane | 16 (31) | 15 (29) | 0.830 |
FOLFIRINOX | 0 (0) | 5 (10) | 0.022 |
FOLFOX | 0 (0) | 4 (8) | 0.041 |
Other | 2 (4) | 9 (17) |
CHT + mEHT, n (%) | CHT, n (%) | P value | |
DCR | 53 (95) | 40 (58) | < 0.001 |
PR | 29 (52) | 13 (14) | < 0.001 |
SD | 24 (43) | 27 (28) | 0.064 |
PD | 3 (5) | 56 (58) | < 0.001 |
- Citation: Fiorentini G, Sarti D, Ranieri G, Gadaleta CD, Fiorentini C, Milandri C, Mambrini A, Guadagni S. Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients. World J Clin Oncol 2021; 12(11): 1064-1071
- URL: https://www.wjgnet.com/2218-4333/full/v12/i11/1064.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i11.1064